On Friday, Iterum Therapeutics Plc (NASDAQ: ITRM) was 7.27% up from the session before settling in for the closing price of $0.44. A 52-week range for ITRM has been $0.36 – $3.02.
During the last 5-year period, the sales growth of Healthcare Sector giant was 58.85%. When this article was written, the company’s average yearly earnings per share was at 25.84%. With a float of $52.33 million, this company’s outstanding shares have now reached $52.79 million.
Iterum Therapeutics Plc (ITRM) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Iterum Therapeutics Plc stocks. The insider ownership of Iterum Therapeutics Plc is 0.87%, while institutional ownership is 2.52%. The most recent insider transaction that took place on Nov 18 ’25, was worth 2,191. In this transaction Director of this company bought 6,000 shares at a rate of $0.37, taking the stock ownership to the 241,001 shares. Before that another transaction happened on Aug 08 ’25, when Company’s Director bought 15,000 for $0.72, making the entire transaction worth $10,854. This insider now owns 235,001 shares in total.
Iterum Therapeutics Plc (ITRM) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.12 earnings per share (EPS) during the time that was better than consensus figure (set at -0.24) by 0.12. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 25.84% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 22.77% during the next five years compared to 58.85% growth over the previous five years of trading.
Iterum Therapeutics Plc (NASDAQ: ITRM) Trading Performance Indicators
You can see what Iterum Therapeutics Plc (ITRM) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.96. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 63.90.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.75, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.31 in one year’s time.
Technical Analysis of Iterum Therapeutics Plc (ITRM)
Looking closely at Iterum Therapeutics Plc (NASDAQ: ITRM), its last 5-days average volume was 0.98 million, which is a jump from its year-to-date volume of 0.7 million. As of the previous 9 days, the stock’s Stochastic %D was 46.80%.
During the past 100 days, Iterum Therapeutics Plc’s (ITRM) raw stochastic average was set at 17.22%, which indicates a significant decrease from 58.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0562 in the past 14 days, which was higher than the 0.0524 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.6019, while its 200-day Moving Average is $0.8998. However, in the short run, Iterum Therapeutics Plc’s stock first resistance to watch stands at $0.5254. Second resistance stands at $0.5788. The third major resistance level sits at $0.6090. If the price goes on to break the first support level at $0.4418, it is likely to go to the next support level at $0.4116. Should the price break the second support level, the third support level stands at $0.3582.
Iterum Therapeutics Plc (NASDAQ: ITRM) Key Stats
There are 52,788K outstanding shares of the company, which has a market capitalization of 24.92 million. As of now, sales total 0 K while income totals -24,770 K. Its latest quarter income was 390 K while its last quarter net income were -8,980 K.
